|
41
|
127
|
6xv3A |
Crystal structure of brd4-bd1 with compound 3 |
|
42
|
125
|
6xvcB |
Crystal structure of brd4-bd1 with compound 1 |
|
40
|
127
|
6xuzA |
Crystal structure of brd4-bd1 with compound 4 |
|
33
|
106
|
6viwA |
Brd4_bromodomain1 complex with pyrrolopyridone compound 18 |
|
35
|
106
|
6vizA |
Brd4_bromodomain1 complex with pyrrolopyridone compound 27 |
|
41
|
107
|
6vixA |
Brd4_bromodomain2 complex with pyrrolopyridone compound 18 |
|
40
|
127
|
6p05A |
Bromodomain-containing protein 4 (brd4) bromodomain 1 (bd1) complexed with compound 27 |
|
42
|
126
|
6yinA |
Crystal structure of the first bromodomain of brd4 in complex with a benzo-diazepine ligand |
|
45
|
126
|
6uwuA |
Crystal structure of the first bromodomain of human brd4 in complex with the inhibitor zl0516 |
|
43
|
127
|
6swqAAA |
N-terminal bromodomain of human brd4 with ibet-bd2 (gsk046) |
|
39
|
125
|
6swnAAA |
N-terminal bromodomain of human brd4 with ibet-bd1 (gsk778) |
|
38
|
123
|
6v1lA |
Crystal structure of the first bromodomain (bd1) of human brd4 bound to bi9564 |
|
44
|
126
|
6v1uA |
Crystal structure of the first bromodomain (bd1) of human brd4 bound to tp-472 |
|
44
|
126
|
6v0uA |
Crystal structure of the first bromodomain (bd1) of human brd4 bound to bromosporine |
|
43
|
127
|
6v1kA |
Crystal structure of the first bromodomain (bd1) of human brd4 bound to bi7273 |
|
44
|
125
|
6jj5A |
Brd4 in complex with 259 |
|
41
|
123
|
6ji4A |
Brd4-bd1 bound with ligand 138 |
|
42
|
124
|
6ji3A |
Brd4-bd1 bound with ligand 103 |
|
39
|
125
|
6vujA |
Crystal structure of brd4 bromodomain 1 with n-methylpyrrolidin-2-one (nmp) derivative 15c (n,n-diethyl-3',4'-dimethoxy-6-(1-methyl-5-oxopyrrolidin-3-yl)-[1,1'-biphenyl]-3-sulfonamide) |
|
39
|
122
|
6ji5A |
Brd4-bd1 bound with ligand 167 |
|
46
|
126
|
6vubA |
Crystal structure of brd4 bromodomain 1 with n-methylpyrrolidin-2-one (nmp) derivative 5 (1-methyl-4-phenylpyrrolidin-2-one) |
|
43
|
126
|
6vucA |
Crystal structure of brd4 bromodomain 1 with n-methylpyrrolidin-2-one (nmp) derivative 7b (1-methyl-4-(4-(piperidin-1-ylsulfonyl)phenyl)pyrrolidin-2-one) |
|
43
|
125
|
6jj6A |
Brd4 in complex with 500 |
|
44
|
126
|
6vufA |
Crystal structure of brd4 bromodomain 1 with n-methylpyrrolidin-2-one (nmp) derivative 7h (4-(1-methyl-5-oxopyrrolidin-3-yl)-n-propylbenzenesulfonamide) |
|
41
|
125
|
6jjbA |
Brd4 in complex with zzm1 |
|
44
|
125
|
6jj3A |
Brd4 in complex with 138a |
|
42
|
127
|
6tpxAAA |
N-terminal bromodomain of human brd4 with 1-((1-acetylpiperidin-4-yl)methyl)-2-(4-hydroxy-3,5-dimethylphenyl)-n-methyl-1h-benzo[d]imidazole-5-carboxamide |
|
44
|
125
|
6tpzAAA |
N-terminal bromodomain of human brd4 with 5-(1-(1,3-dimethoxypropan-2-yl)-5-morpholino-1h-benzo[d]imidazol-2-yl)-1,3-dimethylpyridin-2(1h)-one |
|
42
|
127
|
6tpyAAA |
N-terminal bromodomain of human brd4 with 1,3-dimethyl-5-(1-((tetrahydro-2h-pyran-4-yl)methyl)-1h-benzo[d]imidazol-2-yl)pyridin-2(1h)-one |
|
42
|
127
|
6g0dA |
Brd4 (bd1) in complex with apsc-derived ligands (e.g. ly294002) |
|
47
|
127
|
6g0fA |
Brd4 (bd1) in complex with docking-derived ligand |
|
42
|
125
|
6g0gA |
Brd4 (bd1) in complex with apsc-derived ligands (e.g. sulfasalazine) |
|
42
|
125
|
6g0eA |
Brd4 (bd1) in complex with apsc-derived ligands |
|
42
|
127
|
6g0hA |
Brd4 (bd1) in complex with apsc-derived ligands (e.g. sslh01 a sulfasalazine derivate) |
|
45
|
127
|
6uvmA |
Cocrystal of brd4(d1) with a methyl carbamate thiazepane inhibitor |
|
43
|
127
|
6uvjA |
Cocrystal of brd4(d1) with a methyl carbamate thiazepane inhibitor |
|
44
|
127
|
6uwxA |
Cocrystal of brd4(d1) with a ethyl carbamate thiazepane inhibitor |
|
26
|
97
|
6sisC |
Crystal structure of macrocyclic protac 1 in complex with the second bromodomain of human brd4 and pvhl:elonginc:elonginb |
|
21
|
104
|
6sisB |
Crystal structure of macrocyclic protac 1 in complex with the second bromodomain of human brd4 and pvhl:elonginc:elonginb |
|
34
|
111
|
6sisA |
Crystal structure of macrocyclic protac 1 in complex with the second bromodomain of human brd4 and pvhl:elonginc:elonginb |
|
40
|
149
|
6sisD |
Crystal structure of macrocyclic protac 1 in complex with the second bromodomain of human brd4 and pvhl:elonginc:elonginb |
|
44
|
126
|
6prtA |
Crystal structure of brd4 bromodomain 1 with n-methylpyrrolidin-2-one (nmp) derivative 10 (methyl [(3r)-1-methyl-5-oxopyrrolidin-3-yl]acetate) |
|
44
|
126
|
6ps9A |
Crystal structure of brd4 bromodomain 1 with n-methylpyrrolidin-2-one (nmp) derivative 17 (5-{2-[(3r)-1-methyl-5-oxopyrrolidin-3-yl]ethyl}-2,3,4,5-tetrahydro-1h-pyrido[4,3-b]indol-1-one) |
|
41
|
125
|
6psbA |
Crystal structure of brd4 bromodomain 1 with n-methylpyrrolidin-2-one (nmp) derivative 18 (5-{[(3r)-1-methyl-5-oxopyrrolidin-3-yl]methyl}-2,3,4,5-tetrahydro-1h-pyrido[4,3-b]indol-1-one) |
|
44
|
127
|
6i7yA |
Crystal structure of the first bromodomain of brd4 in complex with rt56 |
|
42
|
127
|
6i7xA |
Crystal structure of the first bromodomain of brd4 in complex with rt53 |
|
44
|
128
|
6in1A |
Crystal structure of the first bromodomain of brd4 in complex with 18-crown-6 |
|
44
|
126
|
6se4A |
Crystal structure of the first bromodomain of human brd4 in complex with (+)-jd1, an organometallic bet bromodomain inhibitor |
|
45
|
127
|
6s25A |
Crystal structure of the first bromodomain of brd4 in complex with a benzodiazepine ligand |
|
38
|
127
|
6mh1A |
Crystal structure of the first bromodomain of human brd4 in complex with hu-10, a 1,4,5-trisubstituted imidazole analogue |
